OWC Pharmaceutical Research Corp.
Other OTCTotal Valuation
OWC Pharmaceutical Research Corp. carries a market capitalization of 4,975.00, placing it among publicly traded companies globally. Its enterprise value stands at 605,304.04, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4,975.00 |
| Enterprise Value | 605,304.04 |
Share Statistics
OWC Pharmaceutical Research Corp. currently has 244.48M shares outstanding.
| Shares Outstanding | 244.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
OWC Pharmaceutical Research Corp. trades at a trailing price-to-earnings ratio of 1.87.
| PE Ratio | 1.87 |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | -0.50 |
| P/FCF Ratio | -0.75 |
| P/OCF Ratio | -0.74 |
Financial Position
OWC Pharmaceutical Research Corp. maintains a current ratio of 3.12, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.12 |
| Quick Ratio | 2.70 |
| Debt / Equity | -1.17 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 44.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -6.02 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
EBITDA reached -3.76M, while operating income came in at -3.77M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -3.77M |
| Pretax Income | 1.34M |
| Net Income | 1.34M |
| EBITDA | -3.76M |
| EBIT | -3.77M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
OWC Pharmaceutical Research Corp. holds 1.47M in cash and equivalents against 47,000.00 in total debt, resulting in a net debt position of -1.46M. Total book value stands at -23.43M, with working capital of 1.15M providing operational flexibility.
| Cash & Cash Equivalents | 1.47M |
| Total Debt | 47,000.00 |
| Net Debt | -1.46M |
| Equity (Book Value) | -23.43M |
| Book Value Per Share | -0.12 |
| Working Capital | 1.15M |
Cash Flow
OWC Pharmaceutical Research Corp. produced -2.74M in operating cash flow over the past twelve months. After subtracting -7,035.00 in capital expenditures, free cash flow totaled -2.75M - equivalent to -0.01 per share.
| Operating Cash Flow | -2.74M |
| Capital Expenditures | -7,035.00 |
| Free Cash Flow | -2.75M |
| FCF Per Share | -0.01 |
Dividends & Yields
The company's payout ratio of -23.78 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -23.78 |
| Shareholder Yield | 0.01 |
| FCF Yield | -133.46 |
Stock Splits
OWC Pharmaceutical Research Corp.'s most recent stock split took place on October 26, 2012 with a 100:1 split ratio.
| Last Split Date | 10/26/2012 |
| Split Ratio | 100:1 |
Scores
OWC Pharmaceutical Research Corp. posts an Altman Z-Score of -24.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.53 |